Marker Therapeutics, Inc. announced that it has completed the construction and qualification of its cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport. The facility will allow production of MultiTAA-specific T cell products according to U.S. Food and Drug Administration guidelines and is designed to be scalable using modular processes. The company has initiated the technology transfer process and expects the cGMP manufacturing facility to be fully operational in the first half of 2021. The manufacturing of the company’s MultiTAA-specific T cell therapy for AML begins with collecting T cells from healthy donors. The T cells are subsequently sent to the company’s facility, where the company isolates and selectively expands naturally occurring T cells that can recognize up to five unique tumor antigens. These tumor-specific T cells are then cryopreserved and shipped to clinical centers to be infused into the patient. Prior to completing the tech transfer and receiving regulatory approval for the cGMP manufacture, the company will continue to manufacture its MultiTAA-specific T cell therapy at the Baylor College of Medicine to support the company-sponsored AML trial.